Literature DB >> 29199427

Predictive value of routine point-of-care cardiac troponin T measurement for prehospital diagnosis and risk-stratification in patients with suspected acute myocardial infarction.

Martin B Rasmussen1, Carsten Stengaard1, Jacob T Sørensen1, Ingunn S Riddervold2, Troels M Hansen2, Matthias Giebner3, Claus-Henrik Rasmussen4, Hans E Bøtker1, Christian J Terkelsen1.   

Abstract

OBJECTIVE: The purpose of this study was to determine the predictive value of routine prehospital point-of-care cardiac troponin T measurement for diagnosis and risk stratification of patients with suspected acute myocardial infarction. METHODS AND
RESULTS: All prehospital emergency medical service vehicles in the Central Denmark Region were equipped with a point-of-care cardiac troponin T device (Roche Cobas h232) for routine use in all patients with a suspected acute myocardial infarction. During the study period, 1 June 2012-30 November 2015, prehospital point-of-care cardiac troponin T measurements were performed in a total of 19,615 cases seen by the emergency medical service and 18,712 point-of-care cardiac troponin T measurements in 15,781 individuals were matched with an admission. A final diagnosis of acute myocardial infarction was confirmed in 2187 cases and a total of 2150 point-of-care cardiac troponin T measurements (11.0%) had a value ≥50 ng/l, including 966 with acute myocardial infarction (sensitivity: 44.2%, specificity: 92.8%). Patients presenting with a prehospital point-of-care cardiac troponin T value ≥50 ng/l had a one-year mortality of 24% compared with 4.8% in those with values <50 ng/l, log-rank: p<0.001. The following variables showed the strongest association with mortality in multivariable analysis: point-of-care cardiac troponin T≥50 ng/l (hazard ratio 2.10, 95% confidence interval: 1.90-2.33), congestive heart failure (hazard ratio 1.93, 95% confidence interval: 1.74-2.14), diabetes mellitus (hazard ratio 1.42, 95% confidence interval: 1.27-1.59) and age, one-year increase (hazard ratio 1.08, 95% confidence interval: 1.08-1.09).
CONCLUSIONS: Patients with suspected acute myocardial infarction and a prehospital point-of-care cardiac troponin T ≥50 ng/l have a poor prognosis irrespective of the final diagnosis. Routine troponin measurement in the prehospital setting has a high predictive value and can be used to identify high-risk patients even before hospital arrival so that they may be re-routed directly for advanced care at an invasive centre.

Entities:  

Keywords:  Acute myocardial infarction; cardiac troponin; emergency medical services; point-of-care; prehospital triage/methods

Mesh:

Substances:

Year:  2017        PMID: 29199427     DOI: 10.1177/2048872617745893

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  10 in total

1.  Acute rule-out of non-ST-segment elevation acute coronary syndrome in the (pre)hospital setting by HEART score assessment and a single point-of-care troponin: rationale and design of the ARTICA randomised trial.

Authors:  Goaris W A Aarts; Cyril Camaro; Robert-Jan van Geuns; Etienne Cramer; Roland R J van Kimmenade; P Damman; Pierre M van Grunsven; Eddy Adang; Paul Giesen; Martijn Rutten; Olaf Ouwendijk; Marc E R Gomes; Niels van Royen
Journal:  BMJ Open       Date:  2020-02-17       Impact factor: 2.692

Review 2.  Geospatial Science and Point-of-Care Testing: Creating Solutions for Population Access, Emergencies, Outbreaks, and Disasters.

Authors:  Gerald J Kost
Journal:  Front Public Health       Date:  2019-11-26

3.  Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study.

Authors:  Tonje R Johannessen; Odd Martin Vallersnes; Sigrun Halvorsen; Anne Cecilie K Larstorp; Ibrahimu Mdala; Dan Atar
Journal:  Open Heart       Date:  2020-07

4.  Prehospital stratification in acute chest pain patient into high risk and low risk by emergency medical service: a prospective cohort study.

Authors:  Kristoffer Wibring; Markus Lingman; Johan Herlitz; Sinan Amin; Angela Bång
Journal:  BMJ Open       Date:  2021-04-15       Impact factor: 2.692

5.  Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study.

Authors:  Rudolf T Tolsma; Marion J Fokkert; Dominique N van Dongen; Erik A Badings; Aize van der Sluis; Robbert J Slingerland; Esther van 't Riet; Jan Paul Ottervanger; Arnoud W J van 't Hof
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-02-08

6.  Prehospital risk assessment in patients suspected of non-ST-segment elevation acute coronary syndrome: a systematic review and meta-analysis.

Authors:  Jesse P A Demandt; Jo M Zelis; Arjan Koks; Geert H J M Smits; Pim van der Harst; Pim A L Tonino; Lukas R C Dekker; Marcel van Het Veer; Pieter-Jan Vlaar
Journal:  BMJ Open       Date:  2022-04-05       Impact factor: 2.692

7.  Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study.

Authors:  Tonje R Johannessen; Dan Atar; Odd Martin Vallersnes; Anne Cecilie K Larstorp; Ibrahimu Mdala; Sigrun Halvorsen
Journal:  BMJ Open       Date:  2021-02-24       Impact factor: 2.692

8.  Development of an Electrochemical Immunosensor for Detection of Cardiac Troponin I at the Point-of-Care.

Authors:  Tsung-Han Lee; Lung-Chieh Chen; Erick Wang; Chin-Cheng Wang; Yan-Ren Lin; Wen-Liang Chen
Journal:  Biosensors (Basel)       Date:  2021-06-26

9.  Feasibility of prehospital identification of non-ST-elevation myocardial infarction by ECG, troponin and echocardiography.

Authors:  Lars Jacobsen; Bjørnar Grenne; Roy Bjørkholt Olsen; Jarle Jortveit
Journal:  Emerg Med J       Date:  2022-01-21       Impact factor: 3.814

Review 10.  Pre-hospital point-of-care troponin measurement: a clinical example of its additional value.

Authors:  G W A Aarts; K van der Wulp; C Camaro
Journal:  Neth Heart J       Date:  2020-10       Impact factor: 2.854

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.